HCV World CAB Meeting on HCV Generics and Diagnostics

In July 2017, 37 treatment activists from 17 countries, including 14 low- and middle-income countries (LMICs), met with representatives from three generics and three diagnostics companies. This HCV World CAB meeting was an opportunity for activists to present demands and obtain strategic information from companies on critical access issues in LMICs relating to pricing policies, registration, and procurement.

Access the report from the meeting here.